4d
Zacks Small Cap Research on MSNIMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.
The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health.
Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)CAB and Oryzon establish primary and ...
Back to top Dr. Balachandran is affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research. The phase 1 clinical trial was sponsored by Memorial Sloan Kettering Cancer Center. The ...
The materials explore and explain voluntary participation, phases of clinical research, and privacy and confidentiality in research. The materials will be housed in the ASH Research Collaborative ...
Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...
THE US headquartered clinical research firm Celerion has announced it will relocate its Belfast operation to the new Queen’s ...
In response to these Phase 1 events, Septerna has initiated non-clinical studies to investigate the underlying mechanism behind the observed effect. “Our extensive preclinical research and toxicology ...
Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical trials and attract more research opportunities to North Carolina.
Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results